Horizon Therapeutics Public Limited (NASDAQ:HZNP) Given Average Recommendation of “Buy” by Analysts

Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) have received a consensus recommendation of “Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $133.67.

A number of equities research analysts have weighed in on HZNP shares. Wells Fargo & Company reiterated a “buy” rating and issued a $133.00 target price on shares of Horizon Therapeutics Public in a report on Friday, April 8th. Oppenheimer started coverage on Horizon Therapeutics Public in a report on Monday, March 14th. They issued an “outperform” rating and a $140.00 target price for the company. Morgan Stanley lifted their target price on Horizon Therapeutics Public from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 2nd. StockNews.com started coverage on Horizon Therapeutics Public in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Piper Sandler lowered their target price on Horizon Therapeutics Public from $143.00 to $133.00 in a report on Wednesday, January 26th.

Shares of HZNP opened at $90.43 on Friday. Horizon Therapeutics Public has a 1 year low of $82.51 and a 1 year high of $120.54. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.57 and a quick ratio of 3.30. The company has a market capitalization of $20.79 billion, a price-to-earnings ratio of 24.78, a price-to-earnings-growth ratio of 1.26 and a beta of 1.11. The business has a 50-day moving average of $104.33 and a 200-day moving average of $102.04.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.20. Horizon Therapeutics Public had a return on equity of 32.08% and a net margin of 22.87%. The company had revenue of $885.25 million during the quarter, compared to the consensus estimate of $866.39 million. During the same period last year, the company earned $0.03 earnings per share. The firm’s revenue was up 158.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Horizon Therapeutics Public will post 5.59 EPS for the current year.

In other Horizon Therapeutics Public news, CFO Paul W. Hoelscher sold 663 shares of the firm’s stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $110.00, for a total value of $72,930.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Paul W. Hoelscher sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $114.71, for a total value of $5,735,500.00. Following the completion of the sale, the chief financial officer now directly owns 1,049 shares of the company’s stock, valued at approximately $120,330.79. The disclosure for this sale can be found here. Insiders sold 530,624 shares of company stock valued at $57,651,384 in the last three months. Insiders own 2.50% of the company’s stock.

Large investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in Horizon Therapeutics Public in the fourth quarter worth $250,526,000. Marshall Wace LLP boosted its position in Horizon Therapeutics Public by 3,782.6% in the fourth quarter. Marshall Wace LLP now owns 1,656,679 shares of the biopharmaceutical company’s stock worth $178,522,000 after purchasing an additional 1,614,010 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Horizon Therapeutics Public in the fourth quarter worth $149,271,000. 1832 Asset Management L.P. boosted its position in Horizon Therapeutics Public by 1,492.5% in the fourth quarter. 1832 Asset Management L.P. now owns 1,406,500 shares of the biopharmaceutical company’s stock worth $152,084,000 after purchasing an additional 1,318,180 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in Horizon Therapeutics Public by 922.2% in the first quarter. Assenagon Asset Management S.A. now owns 1,123,250 shares of the biopharmaceutical company’s stock worth $118,177,000 after purchasing an additional 1,013,364 shares during the last quarter. 88.39% of the stock is currently owned by institutional investors.

Horizon Therapeutics Public Company Profile (Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Read More

Analyst Recommendations for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.